Radiopharm Theranostics Ltd (RADX) News

New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution

Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]